AU2020287599B2 - Pyrrolidine compounds - Google Patents

Pyrrolidine compounds Download PDF

Info

Publication number
AU2020287599B2
AU2020287599B2 AU2020287599A AU2020287599A AU2020287599B2 AU 2020287599 B2 AU2020287599 B2 AU 2020287599B2 AU 2020287599 A AU2020287599 A AU 2020287599A AU 2020287599 A AU2020287599 A AU 2020287599A AU 2020287599 B2 AU2020287599 B2 AU 2020287599B2
Authority
AU
Australia
Prior art keywords
tert
methyl
oxo
compound
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020287599A
Other languages
English (en)
Other versions
AU2020287599A1 (en
Inventor
Nuria Diaz Buezo
Celia Lafuente Blanco
Jose Antonio Martinez Perez
Julian PRIEGO SOLER
Gema Consuelo SANZ GIL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2020287599A1 publication Critical patent/AU2020287599A1/en
Application granted granted Critical
Publication of AU2020287599B2 publication Critical patent/AU2020287599B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2020287599A 2019-06-07 2020-06-03 Pyrrolidine compounds Active AU2020287599B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382477.8 2019-06-07
EP19382477 2019-06-07
PCT/US2020/035825 WO2020247429A1 (en) 2019-06-07 2020-06-03 Pyrrolidine compounds

Publications (2)

Publication Number Publication Date
AU2020287599A1 AU2020287599A1 (en) 2022-01-06
AU2020287599B2 true AU2020287599B2 (en) 2023-10-19

Family

ID=66821161

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020287599A Active AU2020287599B2 (en) 2019-06-07 2020-06-03 Pyrrolidine compounds

Country Status (25)

Country Link
US (3) US11286249B2 (enExample)
EP (1) EP3980409A1 (enExample)
JP (5) JP6940717B2 (enExample)
KR (3) KR102720992B1 (enExample)
CN (1) CN114008021B (enExample)
AU (1) AU2020287599B2 (enExample)
BR (1) BR112021023347A2 (enExample)
CL (1) CL2021003202A1 (enExample)
CO (1) CO2021016295A2 (enExample)
CR (1) CR20210602A (enExample)
DO (1) DOP2021000254A (enExample)
EA (1) EA202193007A1 (enExample)
EC (1) ECSP21088515A (enExample)
IL (2) IL288174B2 (enExample)
JO (1) JOP20210319B1 (enExample)
MA (1) MA56115A (enExample)
MX (2) MX2021014913A (enExample)
MY (1) MY200810A (enExample)
PE (1) PE20220134A1 (enExample)
PH (1) PH12021553062A1 (enExample)
SA (1) SA521431048B1 (enExample)
SG (1) SG11202113244UA (enExample)
UA (1) UA128540C2 (enExample)
WO (1) WO2020247429A1 (enExample)
ZA (1) ZA202109251B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023078333A1 (zh) 2021-11-03 2023-05-11 上海拓界生物医药科技有限公司 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途
EP4469435A1 (en) * 2022-01-26 2024-12-04 Eli Lilly and Company Pyrrolidine compounds
US20260234125A1 (en) * 2023-03-24 2026-08-13 Shanghai Jingxin Biomedical Co., Ltd. Cyclic amine derivative, and composition and use thereof
WO2024217537A1 (zh) * 2023-04-21 2024-10-24 深圳信立泰药业股份有限公司 一种叔胺类化合物及其制备方法和医药用途
TW202444710A (zh) 2023-05-11 2024-11-16 大陸商江蘇恆瑞醫藥股份有限公司 一種脂蛋白化合物晶型及其製備方法
CN122167331A (zh) 2023-05-19 2026-06-09 深圳信立泰药业股份有限公司 一种磺酰胺类化合物及其制备方法和医药用途
IL324569A (en) 2023-06-30 2026-01-01 Lilly Co Eli Therapeutic uses and doses of lp(a) disrupter compounds
JP2026524960A (ja) 2023-07-21 2026-07-24 イーライ リリー アンド カンパニー Ｌｐ（ａ）低下活性を有するピペリジン化合物
KR20260041098A (ko) 2023-07-21 2026-03-26 일라이 릴리 앤드 캄파니 Lp(a) 저하 활성을 갖는 피롤리딘 화합물
CN121548567A (zh) 2023-07-21 2026-02-17 伊莱利利公司 具有Lp(a)降低活性的哌啶、吗啉和四氢哒嗪化合物
KR20260041097A (ko) 2023-07-21 2026-03-26 일라이 릴리 앤드 캄파니 Lp(a) 저하 활성을 갖는 피롤리딘 화합물
CN119490445A (zh) * 2023-08-15 2025-02-21 深圳信立泰药业股份有限公司 一种酰基类化合物及其制备方法和医药用途
CN122535600A (zh) * 2023-11-17 2026-08-07 上海翊石医药科技有限公司 一种取代的2-(吡咯烷-3-基)乙酸的衍生物及其制备方法和用途
CN122270439A (zh) * 2023-11-20 2026-06-23 上海齐鲁制药研究中心有限公司 一种多环类衍生物、其制备方法和应用
WO2025237188A1 (zh) * 2024-05-14 2025-11-20 石家庄以岭药业股份有限公司 一种LP(a)抑制剂化合物及其应用
WO2025255324A1 (en) * 2024-06-06 2025-12-11 Lapis Therapeutics, Inc. Inhibitors of lipoprotein(a) assembly
CN121627662A (zh) * 2024-09-05 2026-03-10 成都康弘药业集团股份有限公司 芳基丙酸化合物及其制备方法与用途
WO2026061518A1 (zh) * 2024-09-23 2026-03-26 上海京新生物医药有限公司 一种环状胺衍生物的固体形式、制备方法及药物组合物
WO2026098459A1 (zh) * 2024-11-06 2026-05-15 上海翊石医药科技有限公司 一种取代的2-(吡咯烷-3-基)乙酸衍生物的晶型及其制备方法和用途
US20260130887A1 (en) * 2024-11-14 2026-05-14 Eli Lilly And Company Oral compositions comprising lp(a) inhibitor compounds
WO2026108936A1 (zh) * 2024-11-20 2026-05-28 深圳信立泰药业股份有限公司 一种化合物a可药用盐以及包含该化合物a可药用盐的药物组合物
WO2026108938A1 (zh) * 2024-11-20 2026-05-28 深圳信立泰药业股份有限公司 一种化合物a或其盐的无定型以及包含该无定形的药物组合物
WO2026119122A1 (zh) * 2024-12-02 2026-06-11 上海喆邺生物科技有限公司 一种苯丙酸衍生物及其医药用途
WO2026130543A1 (zh) * 2024-12-20 2026-06-25 上海维亚聃诚创业孵化器管理有限公司 多芳香环化合物、其组合物及用途
WO2026145708A1 (zh) * 2025-01-02 2026-07-09 上海喆邺生物科技有限公司 一种芳香酸类化合物及其医药用途
CN121135622A (zh) * 2025-04-11 2025-12-16 柴永帅 杂环化合物及其药物组合物和应用
CN121609698B (zh) * 2026-01-30 2026-06-02 山东京新药业有限公司 一种莫伐培林及中间体的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452521A1 (en) * 2001-08-17 2004-09-01 Eisai Co., Ltd. Cyclic compound and ppar agonist
WO2005068412A1 (en) * 2003-12-24 2005-07-28 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
WO2005068410A1 (en) * 2003-12-24 2005-07-28 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685325B1 (fr) * 1991-12-20 1994-02-04 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
KR101133862B1 (ko) 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 Ｔａａｒ 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민
JP2019505508A (ja) 2016-02-03 2019-02-28 シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． 複素環置換ｎ−スルホニルベンズアミド誘導体、その製造方法および医薬における使用
CN112321475B (zh) 2020-11-13 2022-06-10 四川大学 一种γ-氨基酸类似物及其合成方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452521A1 (en) * 2001-08-17 2004-09-01 Eisai Co., Ltd. Cyclic compound and ppar agonist
WO2005068412A1 (en) * 2003-12-24 2005-07-28 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
WO2005068410A1 (en) * 2003-12-24 2005-07-28 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses

Also Published As

Publication number Publication date
JP7508422B2 (ja) 2024-07-01
ECSP21088515A (es) 2022-01-31
JP2024123111A (ja) 2024-09-10
DOP2021000254A (es) 2022-01-16
US11286249B2 (en) 2022-03-29
IL321703A (en) 2025-08-01
EA202193007A1 (ru) 2022-03-25
US20260055086A1 (en) 2026-02-26
JP2026126294A (ja) 2026-08-04
EP3980409A1 (en) 2022-04-13
CN114008021B (zh) 2024-11-05
JP6940717B2 (ja) 2021-09-29
IL288174B1 (en) 2025-08-01
JP2021191784A (ja) 2021-12-16
US20220169636A1 (en) 2022-06-02
MY200810A (en) 2024-01-16
CO2021016295A2 (es) 2021-12-10
JOP20210319A1 (ar) 2023-01-30
IL321703B2 (en) 2026-08-01
JP7658014B2 (ja) 2025-04-07
NZ782992A (en) 2025-02-28
MA56115A (fr) 2022-04-13
US12441714B2 (en) 2025-10-14
SG11202113244UA (en) 2021-12-30
AU2020287599A1 (en) 2022-01-06
JP2025098178A (ja) 2025-07-01
KR102720992B1 (ko) 2024-10-24
CL2021003202A1 (es) 2022-09-09
IL288174B2 (en) 2025-12-01
KR20240014618A (ko) 2024-02-01
ZA202109251B (en) 2024-04-24
PH12021553062A1 (en) 2022-08-15
JP2021524498A (ja) 2021-09-13
IL288174A (en) 2022-01-01
KR20230004890A (ko) 2023-01-06
UA128540C2 (uk) 2024-08-07
US20210253559A1 (en) 2021-08-19
CN114008021A (zh) 2022-02-01
KR20220018494A (ko) 2022-02-15
KR102629923B1 (ko) 2024-01-30
WO2020247429A1 (en) 2020-12-10
PE20220134A1 (es) 2022-01-27
IL321703B1 (en) 2026-04-01
MX2025001789A (es) 2025-03-07
CA3140869A1 (en) 2020-12-10
JOP20210319B1 (ar) 2024-12-22
SA521431048B1 (ar) 2024-04-28
CR20210602A (es) 2022-01-06
BR112021023347A2 (pt) 2022-04-12
KR102477481B1 (ko) 2022-12-15
MX2021014913A (es) 2022-01-18

Similar Documents

Publication Publication Date Title
US12441714B2 (en) Pyrrolidine compounds
EP3022192B1 (en) Piperidinyl indole derivatives and their use as complement factor b inhibitors
US20220041576A1 (en) Isoindoline compound, preparation method, pharmaceutical composition and use thereof
US9000182B2 (en) 2H-imidazol-4-amine compounds and their use as BACE inhibitors
EP2443092A1 (en) Bicyclic and tricyclic compounds as kat ii inhibitors
EA016108B1 (ru) [2,6]нафтиридины, применимые в качестве ингибиторов протеинкиназы
US20160002172A1 (en) Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
AU2018228555A1 (en) Azetidine derivative
CA3140869C (en) Pyrrolidine compounds
CN122070289A (zh) 羟基去甲氯胺酮类似物及其用途
EA045074B1 (ru) Соединения пирролидина
AU2024298640A1 (en) Piperidine Compounds with Lp(a) Lowering Activity
WO2025024216A1 (en) PYRROLIDINE COMPOUNDS Lp(a) LOWERING ACTIVITY
AU2024298539A1 (en) PYRROLIDINE COMPOUNDS WITH Lp(a) LOWERING ACTIVITY
WO2025024210A1 (en) Piperidine, morpholine and tetrahydro-pyridazine compounds with lp(a) lowering activity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)